ArticleDiscover oncology2025
The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of COVID-19 vaccination on radiation-induced lung injury in breast cancer patients: a retrospective cohort study.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC).
methodsSCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) and grouped according to the timing of the COVID-19 pandemic. Intergroup comparisons and survival analyses were performed on clinicopathologic characteristics and survival data to explore the differences in morbidity characteristics and survival in SCLC patients before and after the pandemic.
resultsSCLC Patients diagnosed in the post-COVID-19 pandemic tended to have earlier tumor stage, receive chemotherapy (OR 1.14, 95% CI 1.02-1.27, P-value = 0.02) rather than radiotherapy (OR 0.89, 95% CI 0.84-0.96, P-value < 0.01), and have increased time to treatment delay. Balancing follow-up time and constructing improved survival curves, patients with SCLC diagnosed after the pandemic tended to have a worse prognosis.
conclusionsDifferences in some clinicopathologic factors and treatment choices, or the pandemic itself, may result in a tendency for patients with SCLC diagnosed after the pandemic to have a worse prognosis, alerting clinicians to the need to focus on the management and treatment of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.